This first-time in human, single-arm, open-label multicentre Phase I/II study will evaluate the safety, tolerability, anti-tumour activity, cellular kinetics, pharmacodynamics, and immunogenicity of AZD5851 in adult participants with GPC3+ advanced/recurrent HCC, where at least one line of prior therapy has failed/or was intolerable, or participant/investigator decision.
Sponsor
AstraZeneca
Status of enrollment
Accepting new patients
Ages Eligible for Study
Adults aged 18 and older
Genders Eligible for Study
Female and Male
Disease indication
Hepatocellular Carcinoma, Liver Cancer
Principal Investigator
Bridget Keenan, MD, PhD
Contact
Annie Deng
Additional study eligibility details can be found at UCSF Clinical Trials.